AKUMS Akums Drugs Q3 FY26 results (Oct–Dec 2025) and concall
Akums Drugs reported a strong Q3 FY26, with double-digit revenue and EBITDA growth driven by robust performance in its CDMO and international branded formulation segments. Despite continued pricing pressure in the API business and a decline in trade generics, overall profitability improved significantly. The company is actively pursuing global expansion with projects in Europe and Zambia, while also focusing on operational efficiencies and strategic capital allocation.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 9.5%, net profit down 31.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 328 | 337 | 329 | 332 | 309 −6% | 369 +9% |
| EBITDA | 43 | 34 | 18 | 44 | 17 −60% | 25 −26% |
| Net profit | 50 | 41 | 28 | 45 | 23 −54% | 28 −32% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
